GlassScriptPhysician profile
Jeffrey Cooper
NPI 1295800050
$52,327.38
in general payments reported to CMS, 2019-2025
27 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 86% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,232 · 2020: $426 · 2021: $366 · 2022: $25K · 2023: $16K · 2024: $882 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $2,931 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,292.70 |
| Food and Beverage | $2,930.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $47,746.68 | 2019-2025 | |
| Alcon Vision LLC | $751.80 | 2019-2024 | Total30, Rocklatan, Dailies Total1 |
| Coopervision INC. | $652.93 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Paragon Crt |
| Bausch & Lomb Americas INC. | $362.30 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $350.49 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $291.72 | 2019-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $220.53 | 2019-2023 | |
| Allergan, INC. | $206.94 | 2019-2022 | |
| Sight Sciences, INC. | $204.18 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $183.99 | 2019-2021 | |
| Shire North American Group INC | $174.13 | 2019 | |
| Lombart Brothers, INC. | $150.00 | 2019 | |
| Dompe US, INC. | $142.13 | 2021-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $140.67 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $135.22 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $130.19 | 2020-2023 | Tobradex St |
| Harrow Eye, LLC | $80.09 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $77.28 | 2019-2023 | Acuvue |
| Aerie Pharmaceuticals, INC. | $66.88 | 2019 | |
| Rxsight INC | $48.35 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Amgen INC. | $38.31 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $36.79 | 2020 | |
| Abbvie INC. | $36.13 | 2022-2023 | Lumigan |
| Horizon Therapeutics Plc | $35.53 | 2023 | Tepezza |
| Abb Con-Cise Optical Group LLC | $27.48 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.